Clinician-Scientist
Hematology
Dr. Rodger E. Tiedemann, MD
|
|
Give Review
Doctor Rodger E. Tiedemann, MD works in the field of Hematology. Rodger Tiedemann is a published physician as well. He has 17 publications published. The latest was: Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Publications
- Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
- Identification of molecular vulnerabilities in human multiple myeloma cells by RNAi lethality screening of the druggable genome.
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.
- Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
- Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
- Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Genetic aberrations and survival in plasma cell leukemia.
- RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
- AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
- Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
- A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.
- Cyproheptadine displays preclinical activity in myeloma and leukemia.
Doctors Specialties
- Hematology
Accepted Insurances
- Great West Healthcare-Cigna PPO
Helpful Reviews
Similar Doctors
|
|
Dr. Raoul Tibes, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Surabhi Amar, MD |
|
|
Dr. Ann McCullough, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Harshita R. Paripati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric E. Prommer, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Helen J. Ross, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. John K. Camoriano, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Joseph R. Mikhael, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Craig B. Reeder, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Bruce A. Lenes, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Leslie J. Padrnos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen S. Anderson, MD |
|
|
Joanne L. Schlesinger, NP |